HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.
Science
; 276(5319): 1719-24, 1997 Jun 13.
Article
en En
| MEDLINE
| ID: mdl-9180086
ABSTRACT
In allogeneic bone marrow transplantation (allo-BMT), donor lymphocytes play a central therapeutic role in both graft-versus-leukemia (GvL) and immune reconstitution. However, their use is limited by the risk of severe graft-versus-host disease (GvHD). Eight patients who relapsed or developed Epstein-Barr virus-induced lymphoma after T cell-depleted BMT were then treated with donor lymphocytes transduced with the herpes simplex virus thymidine kinase (HSV-TK) suicide gene. The transduced lymphocytes survived for up to 12 months, resulting in antitumor activity in five patients. Three patients developed GvHD, which could be effectively controlled by ganciclovir-induced elimination of the transduced cells. These data show that genetic manipulation of donor lymphocytes may increase the efficacy and safety of allo-BMT and expand its application to a larger number of patients.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Timidina Quinasa
/
Terapia Genética
/
Leucemia
/
Trasplante de Médula Ósea
/
Transfusión de Linfocitos
/
Enfermedad Injerto contra Huésped
Tipo de estudio:
Etiology_studies
Límite:
Humans
Idioma:
En
Revista:
Science
Año:
1997
Tipo del documento:
Article
País de afiliación:
Italia